Anika Therapeutics (NASDAQ:ANIK) Posts Earnings Results, Beats Estimates By $0.27 EPS

Anika Therapeutics (NASDAQ:ANIK) issued its earnings results on Wednesday. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.27, Zacks reports. Anika Therapeutics had a negative return on equity of 5.90% and a negative net margin of 9.52%.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Strong second-quarter performance: Revenue rose 16% to $32.6 million, commercial-channel revenue increased 17%, and adjusted EBITDA reached $7.1 million, the company’s highest quarterly level since 2020.
• Guidance was raised: Anika now expects 2026 total revenue growth of 5%–10%, commercial-channel growth of 12%–18%, OEM growth of 0%–5%, and an adjusted EBITDA margin of 13%–17%.
• Operational improvements are lifting profitability: Gross margin expanded to 65%, supported by manufacturing productivity, better yields, increased throughput, favorable mix, and lean initiatives; management expects margins to remain around 64% or higher in the second half.
• International OA pain-management products and regenerative solutions remained growth drivers, with Cingal up 32%, Monovisc up 24%, and Integrity year-to-date sales up approximately 39% in the quarter.
• Regulatory timing remains uncertain: Hyalofast’s FDA review is continuing after a deficiency letter, while 2027 guidance excludes the previously expected $3 million of U.S. Hyalofast revenue; management also expects second-half profitability to be lower due to OEM order timing and continued pricing pressure.

Anika Therapeutics Price Performance

ANIK traded up $1.44 during midday trading on Wednesday, hitting $16.59. 62,461 shares of the company’s stock traded hands, compared to its average volume of 113,563. The company has a market cap of $220.68 million, a PE ratio of -20.99 and a beta of 0.23. The stock’s fifty day simple moving average is $14.99 and its 200-day simple moving average is $13.61. Anika Therapeutics has a one year low of $7.87 and a one year high of $17.75.

Insider Activity at Anika Therapeutics

In other Anika Therapeutics news, CEO Stephen D. Griffin purchased 12,200 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were bought at an average price of $12.29 per share, for a total transaction of $149,938.00. Following the purchase, the chief executive officer directly owned 36,163 shares in the company, valued at $444,443.27. This trade represents a 50.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John B. Henneman III purchased 5,000 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were acquired at an average price of $14.66 per share, for a total transaction of $73,300.00. Following the acquisition, the director directly owned 54,871 shares in the company, valued at $804,408.86. This represents a 10.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 12.08% of the company’s stock.

Institutional Trading of Anika Therapeutics

Several large investors have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new position in shares of Anika Therapeutics in the 1st quarter valued at approximately $181,000. Cetera Investment Advisers boosted its position in Anika Therapeutics by 93.1% during the second quarter. Cetera Investment Advisers now owns 19,509 shares of the biotechnology company’s stock worth $206,000 after purchasing an additional 9,407 shares during the period. American Century Companies Inc. grew its holdings in Anika Therapeutics by 32.8% during the second quarter. American Century Companies Inc. now owns 44,161 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 10,909 shares during the last quarter. Marshall Wace LLP acquired a new position in Anika Therapeutics during the second quarter valued at approximately $241,000. Finally, Jane Street Group LLC raised its position in shares of Anika Therapeutics by 31.6% in the second quarter. Jane Street Group LLC now owns 22,871 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 5,488 shares during the period. Institutional investors own 91.53% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Anika Therapeutics in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $17.00.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.